EyePoint Pharmaceuticals, Inc. Forecast, price target & analysts
EyePoint Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
EyePoint Pharmaceuticals, Inc. Classifications & Recommendation:
EyePoint Pharmaceuticals, Inc. Price Target
| Target Price | $32.00 |
| Price | $7.42 |
| Potential |
331.27%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target EyePoint Pharmaceuticals, Inc. 2026 .
The average EyePoint Pharmaceuticals, Inc. target price is $32.00.
This is
331.27%
register free of charge
$68.00
816.44%
register free of charge
$18.00
142.59%
register free of charge
|
|
| A rating was issued by 13 analysts: 13 Analysts recommend EyePoint Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the EyePoint Pharmaceuticals, Inc. stock has an average upside potential 2026 of
331.27%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 43.27 | 39.99 |
| 5.98% | 7.58% | |
| EBITDA Margin | -333.51% | 63.31% |
| 104.45% | 118.98% | |
| Net Margin | -302.45% | -440.42% |
| 96.59% | 45.62% |
13 Analysts have issued a sales forecast EyePoint Pharmaceuticals, Inc. 2025 . The average EyePoint Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an EyePoint Pharmaceuticals, Inc. EBITDA forecast 2025. The average EyePoint Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 EyePoint Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average EyePoint Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.32 | -2.56 |
| 27.47% | 10.34% | |
| P/E | negative | |
| EV/Sales | 4.81 |
4 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast for earnings per share. The average EyePoint Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
EyePoint Pharmaceuticals, Inc....
Current EyePoint Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 29 2025 |
| Mizuho |
Locked
➜
Locked
|
Locked | May 16 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 29 2025 |
|
Locked
Mizuho:
Locked
➜
Locked
|
May 16 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Feb 06 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jan 07 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
